Akela total consolidated revenues increase to $7.

Consolidated net gain for the six months ended June 30, 2011 was $0.48 million vs. $0.17 million, for the same period this year 2010. The Company had a cash stability of $0.21 as of June 30, in comparison with $0.14 million as of March 31, 2011.. Akela total consolidated revenues increase to $7.3M for six months ended June 30, 2011 Akela Pharma, Inc. , and PharmaForm, a leading specialty contract company in the region of pharmaceutical dosage type manufacturing and development, announced its financial results for the three and half a year and year finished June 30 today, 2011.The Kaiser Daily Health Policy Report is published for Kaisernetwork.org, a free of charge provider of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Table Kaiser and Company Family members Foundation. All rights reserved.. HIV Therapy May Decrease Risk for Hepatitis B Also, Study Says: – MONDAY, Oct. 12, 2015 – – Not merely does effective HIV therapy thwart the AIDS-causing virus, it could also reduce the risk for hepatitis B illness, a new study says.